Cancer-Focused Vaccinex Joins IPO Party With $46M Offering
Cancer-focused Vaccinex Inc., represented by Hogan Lovells, filed a preliminary $46 million initial public offering on Monday, joining a wave of biotechnology companies that are driving the current IPO surge....To view the full article, register now.
Already a subscriber? Click here to view full article